BioNTech SE (NASDAQ:BNTX) Receives $231.43 Average PT From Analysts
BioNTech SE (NASDAQ:BNTX) Receives $231.43 Average PT From Analysts
BioNTech SE (NASDAQ:BNTX – Get Rating) has been given a consensus rating of "Hold" by the seventeen analysts that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $231.43.
据MarketBeat Ratings报道，目前追踪该股的17位分析师一致给予BioNTech SE(纳斯达克股票代码：BNTX-GET Rating)“持有”的评级。五名分析师对该股的评级为持有建议，四名分析师对该公司发出了买入建议。在去年更新了对该股覆盖范围的经纪商中，12个月的平均目标价为231.43美元。
Several analysts recently issued reports on BNTX shares. The Goldman Sachs Group set a $200.00 price target on shares of BioNTech in a research report on Tuesday, August 9th. Cowen started coverage on shares of BioNTech in a research report on Wednesday, August 17th. They issued a "market perform" rating and a $177.00 target price on the stock. Canaccord Genuity Group raised their target price on shares of BioNTech from $192.00 to $200.00 and gave the company a "buy" rating in a research report on Tuesday, August 9th. Canaccord Genuity Group restated a "buy" rating and issued a $192.00 target price on shares of BioNTech in a research report on Wednesday, July 6th. Finally, UBS Group set a $168.00 target price on shares of BioNTech in a research report on Thursday, June 30th.
几位分析师最近发布了有关BNTX股票的报告。高盛在8月9日周二的一份研究报告中为生物技术公司的股票设定了200.00美元的目标价。考恩在8月17日星期三的一份研究报告中开始报道BioNTech的股票。他们对该股给予了“市场表现”评级和177.00美元的目标价。8月9日，在一份研究报告中，Cancord Genuity Group将BioNTech的股票目标价从192.00美元上调至200.00美元，并给予该公司“买入”评级。7月6日，在一份研究报告中，CANACCORD GENINITY集团重申了买入评级，并为BioNTech的股票设定了192.00美元的目标价。最后，瑞银集团在6月30日星期四的一份研究报告中为BioNTech的股票设定了168.00美元的目标价。
BioNTech Trading Down 1.3 %
BioNTech股价下跌1.3%
Shares of NASDAQ:BNTX opened at $128.35 on Monday. BioNTech has a 52-week low of $117.08 and a 52-week high of $374.58. The company has a market capitalization of $31.15 billion, a P/E ratio of 2.48 and a beta of 0.03. The company has a 50-day simple moving average of $152.89 and a 200 day simple moving average of $154.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.06 and a current ratio of 5.15.
纳斯达克：BNTX周一开盘报128.35美元。BioNTech的52周低点为117.08美元，52周高位为374.58美元。该公司市值为311.5亿美元，市盈率为2.48倍，贝塔系数为0.03。该公司的50日简单移动均线切入位在152.89美元，200日简单移动均线切入位在154.75美元。该公司的负债权益比率为0.01，速动比率为5.06，流动比率为5.15。
Institutional Investors Weigh In On BioNTech
机构投资者买入BioNTech
Several hedge funds and other institutional investors have recently made changes to their positions in BNTX. Captrust Financial Advisors boosted its stake in BioNTech by 6.9% in the second quarter. Captrust Financial Advisors now owns 1,068 shares of the company's stock valued at $159,000 after acquiring an additional 69 shares during the last quarter. Centaurus Financial Inc. boosted its stake in shares of BioNTech by 5.2% in the 1st quarter. Centaurus Financial Inc. now owns 1,448 shares of the company's stock valued at $247,000 after purchasing an additional 71 shares in the last quarter. Exane Derivatives boosted its stake in shares of BioNTech by 13.5% in the 2nd quarter. Exane Derivatives now owns 799 shares of the company's stock valued at $119,000 after purchasing an additional 95 shares in the last quarter. KRS Capital Management LLC purchased a new stake in shares of BioNTech in the 4th quarter valued at $25,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in BioNTech by 66.7% during the 1st quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 250 shares of the company's stock valued at $43,000 after buying an additional 100 shares during the period. 13.77% of the stock is owned by institutional investors.
几家对冲基金和其他机构投资者最近改变了他们在BNTX的头寸。CapTrust Financial Advisors在第二季度将其在BioNTech的持股增加了6.9%。CapTrust Financial Advisors在上个季度增持了69股后，现在拥有1,068股该公司股票，价值15.9万美元。今年第一季度，Centaurus Financial Inc.增持了BioNTech的股份5.2%。半人马座金融公司目前持有1,448股该公司股票，价值24.7万美元，该公司在上个季度又购买了71股。Exane衍生品在第二季度将其在BioNTech的股份增加了13.5%。Exane衍生品现在拥有该公司799股股票，价值11.9万美元，此前在上个季度又购买了95股。KRS Capital Management LLC在第四季度购买了BioNTech的新股，价值25,000美元。最后，洛林·沃尔科特和柯立芝信托顾问公司LLP MA在第一季度将其在BioNTech的头寸提高了66.7%。洛林·沃尔科特和柯立芝信托顾问公司现在拥有250股该公司的股票，价值43,000美元，在此期间又购买了100股。13.77%的股份由机构投资者持有。
About BioNTech
关于BioNTech
(Get Rating)
(获取评级)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.
BioNTech SE是一家生物技术公司，开发和销售治疗癌症和其他传染病的免疫疗法。该公司正在开发FixVac候选产品，包括治疗晚期黑色素瘤的第二阶段临床试验的BNT111、治疗前列腺癌的第一阶段/第二阶段临床试验的BNT112、治疗HPV阳性头颈癌的第二阶段临床试验的BNT113、治疗三阴性乳腺癌的第一阶段临床试验的BNT114、治疗卵巢癌的第一阶段临床试验的BNT115以及治疗非小细胞肺癌的临床前阶段产品BNT116。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on BioNTech (BNTX)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 免费获取StockNews.com关于BioNTech的研究报告(BNTX)
- MarketBeat：回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性？
- 需要关注的2只半导体类股走势逆转
- CrowdStrike是否会从增加每股收益指引中获得提振？
- 小盘股的裁员是楼市的晴雨表吗？
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
获得《BioNTech Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioNTech和相关公司的最新新闻和分析师评级的每日简要摘要。